SEARCH

SEARCH BY CITATION

References

  • 1
    McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000; 6:149156.
  • 2
    Durko M, Brodt P. The metalloproteinases and their inhibitors. In: BrodtP, ed. Cell Adhesion and Invasion in Cancer Metastasis. Austin , TX : RG Landes Co; 1996: 113150.
  • 3
    Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327336.
  • 4
    MacDougall JR, Martisian LM. Contributions of tumor and stro-mal matrix metalloproteinases to tumor progression, invasion, and metastasis. Cancer Metastasis Rev 1995; 14:351362.
  • 5
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:12601270.
  • 6
    Sier CFM, Kubben FJGM, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413417.
  • 7
    Kataoka M, Yamagata S, Akiyama S, et al. Matrix metallopro-teinase 2 and 9 in esophageal cancer: Correlation with organ metastasis. Int J Oncol 1996;8:773779.
  • 8
    Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:53655369.
  • 9
    Oberg A, Hoyhtya M, Tavelin B, et al. Limited value of preoperative analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matix metalloproteinases (TIMP-1, TIMP-2) in co-lorectal cancer. Anticancer Res 2000;20:10851092.
  • 10
    Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000;20:20092014.
  • 11
    Stearns ME, Stearns M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol Res 1996;8:6367.
  • 12
    Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matix metalloproteinases -2–9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer -TIMP-1 as a prognostic marker. Anticancer Res 2000;20:13111316.
  • 13
    Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000;61:111114.
  • 14
    Shen K, Chi C, Lo S, et al. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 2000;20:13071310.
  • 15
    Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Ann N Y Acad Sci 1999;878:212227.
  • 16
    Zucker S, Lysik RM, Zarrabi MH, et al. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53:140146.
  • 17
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248.
  • 18
    Huessen C, Dowdle EB. Electrophoretic analysis of plasmino-gen activators in polyacrylamide gels containing sodium dodecylsul-fate and copolymerized substrates. Anal Biochem 1980; 102:196202.
  • 19
    Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000; 87:12151221.
  • 20
    Maguire PD, Qi W, Lallemand R, Scully SP. Gelatinase and inhibitor expression in soft tissue sarcomas: Lack of correlation with distant metastasis. Oncology 2000;59:139144.
  • 21
    Park MJ, Park IC, Hur JH, et al. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 2000;290:201204.
  • 22
    Farias E, Ranuncolo S, Cresta C, et al. Plasma metalloprotei-nase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer 2000;89:389394.
  • 23
    Furuya M, Ishikura H, Kawarada Y, et al. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol 2000;78:106112.
  • 24
    Sang QA, Douglas DA. Computational sequence analysis of matrix metalloproteinases. J Protein Chem 1996;15:137160.
  • 25
    Coindre J, Bui NBB, Bonichon F, et al. Histopathologic grading in spindle cell soft tissue sarcomas. Cancer 1988;61:23052309.